| Bioactivity | DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy[1]. |
| CAS | 213187-44-1 |
| Sequence | {DOTA}-{d-2Nal}-Cys-Tyr-{d-Trp}-Lys-Val-Cys-Thr (disulfide bridge:Cys2-Cys7) |
| Shortening | {DOTA}-{d-2Nal}-CY-{d-Trp}-KVCT-NH2 (Disulfide bridge: Cys2-Cys7) |
| Formula | C70H95N15O17S2 |
| Molar Mass | 1482.72 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
DOTA-Lanreotide
CAS: 213187-44-1 F: C70H95N15O17S2 W: 1482.72
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.